Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Syros Pharmaceuticals

< Previous 1 2 Next >
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros to Present at JMP Securities 2023 Life Sciences Conference
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros to Participate in Upcoming Investor Conferences in March
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros Announces Clinical Updates and 2023 Strategic Priorities
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros to Participate at Piper Sandler 34th Annual Healthcare Conference
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros to Present at H.C. Wainwright 24th Annual Global Investment Conference
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS TYME
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
Syros to Present at JMP Securities Life Sciences Conference
From Syros Pharmaceuticals
Via Business Wire
Tickers SYRS
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.